tbuckley/cabot-search huggingface dataset:
Stroke Diagnosis and Treatment in the Emergency Department—Reply
Authors: Jagannadha Avasarala
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models.
Authors: John Miller, Matthew J. Barth, Cory Mavis, Ping-Chiao Tsai, Pavel Klener, Francisco Hernandez-Ilizaliturri, Myron S. Czuczman
Journal: Blood (2012)
Prevention and treatment of diabetic foot ulcers
Authors: Jonathan Zhang Ming Lim, Natasha Su Lynn Ng, Cecil Thomas
Journal: Journal of the Royal Society of Medicine (2017)

The rising prevalence of diabetes estimated at 3.6 million people in the UK represents a major public health and socioeconomic burden to our National Health Service. Diabetes and its associated complications are of a growing concern. Diabetes-related foot complications have been identified as the single most common cause of morbidity among diabetic patients. The complicating factor of underlying peripheral vascular disease renders the majority of diabetic foot ulcers asymptomatic until latter evidence of non-healing ulcers become evident. Therefore, preventative strategies including annual diabetic foot screening and diabetic foot care interventions facilitated through a multidisciplinary team have been implemented to enable early identification of diabetic patients at high risk of diabetic foot complications. The National Diabetes Foot Care Audit reported significant variability and deficiencies of care throughout England and Wales, with emphasis on change in the structure of healthcare provision and commissioning, improvement of patient education and availability of healthcare access, and emphasis on preventative strategies to reduce morbidities and mortality of this debilitating disease. This review article aims to summarise major risk factors contributing to the development of diabetic foot ulcers. It also considers the key evidence-based strategies towards preventing diabetic foot ulcer. We discuss tools used in risk stratification and classifications of foot ulcer.
The Feasibility Study for Using FLT3/ITD as a Marker of the Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) by Serial Analysis in Diagnosis, Remission and Relapse.
Authors: Yeo-Kyeoung Kim, Hee-Nam Kim, Il-Kwon Lee, Su-Mi Lee, Hyeok Shim, Moo-Rim Park, Kyeoung-Soo Park, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim
Journal: Blood (2005)
Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide
Authors: Antonia Lopez-Girona, Derek Mendy, Karen Miller, Anita K Gandhi, Jian Kang, Gilles Carmel, Mahan Abbasian, Afshin Mahmoudi, Pilgrim Jackson, Brian Cathers, Emily Rychak, Normand Richard, Helen A Brady, Peter H Schafer, Jilly F Evans, Tom O Daniel, Rajesh Chopra
Journal: Blood (2011)
Clinical significance of biochemical markers in prostate cancer
Authors: M. M. Meshref, O. Youssef, D. Elgayar, M. Kamal
Journal: Journal of Clinical Oncology (2008)

16041 Background: Many strategies have been proposed to enhance the ability of PSA in differentiation of Prostate Cancer from BPH. The present study aimed at evaluating the measurement of serum levels of NSE, TPS and HGF in combination with PSA and f/T PSA in Prostate Cancer patients to assess their diagnostic and prognostic value. Methods: The study was conducted on 72 patients complaining of obstructive symptoms as frequency and urgency. 26 diagnosed as BPH, 21 diagnosed as localized PCa and 25 diagnosed as metastatic PCa. The latter group was divided according to Gleason score into moderately differentiated (n=13) and poorly differentiated adenocarcinoma (n=12). All patients were subjected to TRUS, core needle biopsy and assay of serum tPSA, fPSA measured by chemiluminescent immunometric assay, NSE using electrochemiluminescence immunometric assay,TPS (IRMA) and HGF (ELISA). Corellation with progression free survival was done for metastatic patients. Results: Median values of tPSA was significantly higher in metastatic PCa (group III) compared to localized PCa (group II) and BPH patients (group I) (68, 7.0, 2.0 ng/ml respectively P<0.001), f/T PSA was significantly lower in PCa patients (groupII, group III) compared to BPH patients (0.13, 0.14, 0.2 respectively, P=0.004), TPS was significantly higher in metastatic PCa (140 U/L) compared to group I and group II (77, 65 U/L, respectively P=0.004) and HGF was significantly highest in metastatic PCa patients compared to group 1 and group II (2270, 2132, 1789 pg/ml, respectively, p=0.047). Simultaneous assay of PSA and HGF yielded a sensitivity of 96% in discriminating between BPH from malignant prostate compared to 91% for HGF and 93% for PSA alone. The metastatic PCa group showed a lower progression free survival associated with high NSE levels. Conclusions: The f/tPSA is useful in discriminating between BPH and PCa and thus allowing early intervention and treatment. A cutoff value of 0.24 for f/tPSA is recommended as it detects 87% of cancer cases and at the same time avoids 39% of unnecessary prostate biopsy. Moreover, combining PSA and HGF was more accurate in discriminating between BPH and malignant prostate. High NSE levels are of prognostic significance in patients with metastatic PCa treated with hormonal therapy. No significant financial relationships to disclose.
Financial Conflicts of Interest and the Centers for Disease Control and Prevention’s 2016 Guideline for Prescribing Opioids for Chronic Pain
Authors: Dora H. Lin, Eleanor Lucas, Irene B. Murimi, Andrew Kolodny, G. Caleb Alexander
Journal: JAMA Internal Medicine (2017)

This study identifies levels of support for the 2016 Centers for Disease Control and Prevention guidelines for prescribing opioids for chronic pain and whether financial relationships with opioid manufacturers are associated with opposition to the guidelines.
Caring for the young athlete: past, present and future
Authors: Neeru Jayanthi, Joel Brenner
Journal: British Journal of Sports Medicine (2017)

Caring for the young athlete presents many unique challenges. While there is a growing body of research on the needs of elite level athletes, there is still relatively little evidence or specific recommendations addressing the concerns of the young athlete. By numbers alone, most sports medicine professionals actually care for the millions of young athletes, rather than the smaller proportion of university, professional or Olympic athletes.

The American Medical Society for Sports Medicine (AMSSM) is honoured to contribute to this special issue to provide evidence-based and expert perspectives on the specific needs and concerns relating to younger athletes.

A previous longitudinal cohort study of 453 elite young British athletes outlined the positive benefits of sport, while identifying a knowledge gap of when coaches, parents and athletes should initiate intensive training or specialisation in a single sport.1

Recently, multiple organisations have published general recommendations on youth sports training and sports …
BMET-30. TREATMENT OPTIONS OF LONG TERM SURVIVORS WITH LEPTOMENINGEAL METASTASES AND BREAST CANCER
Authors: Caroline Chaul-Barbosa, Aki Morikawa, Sujata Patil, Adrienne Boire, Lilly Jordan, Raquel Rozner, Andrew Seidman, Elena Pentsova
Journal: Neuro-Oncology (2016)

INTRODUCTION:Leptomeningeal metastases (LM) is a devastating complication of cancer. We previously reported a study of 318 breast cancer (BC) patients with LM with a median survival of 3.5 months. However, 63 (20%) of patients were long term survivors (LTS), alive after 1 year. This study describes treatments received after the LM diagnosis by these LTS.
Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study
Authors: Anna J Podolanczuk, Ganesh Raghu, Michael Y Tsai, Steven M Kawut, Eric Peterson, Rajiv Sonti, Daniel Rabinowitz, Craig Johnson, R Graham Barr, Karen Hinckley Stukovsky, Eric A Hoffman, J Jeffrey Carr, Firas S Ahmed, David R Jacobs, Karol Watson, Steven J Shea, David J Lederer
Journal: Thorax (2017)

We investigated associations of plasma lipoproteins with subclinical interstitial lung disease (ILD) by measuring high attenuation areas (HAA: lung voxels between −600 and −250 Hounsfield units) in 6700 adults and serum MMP-7 and SP-A in 1216 adults age 45–84 without clinical cardiovascular disease in Multi-Ethnic Study of Atherosclerosis. In cross-sectional analyses, each SD decrement in high density lipoprotein cholesterol (HDL-C) was associated with a 2.12% HAA increment (95% CI 1.44% to 2.79%), a 3.53% MMP-7 increment (95% CI 0.93% to 6.07%) and a 6.37% SP-A increment (95% CI 1.35% to 11.13%), independent of demographics, smoking and inflammatory biomarkers. These findings support a novel hypothesis that HDL-C might influence subclinical lung injury and extracellular matrix remodelling.
Experience with a Modified Nijmegen-Bethesda Method for Measurement of Inhibitors in Hemophilia Patients: The CDC Inhibitor Surveillance Pilot Project.
Authors: Connie H. Miller, S. Jean Platt, Thomas Abshire, Doreen Brettler, Paula Brockenstedt, Jorge DiPaola, Gita Massey, Anne Neff, Amy Shapiro, Michael Tarantino, Brian Wicklund, Melissa Creary, J. Michael Soucie
Journal: Blood (2007)
Avian W and mammalian Y chromosomes convergently retained dosage-sensitive regulators
Authors: Daniel W Bellott, Helen Skaletsky, Ting-Jan Cho, Laura Brown, Devin Locke, Nancy Chen, Svetlana Galkina, Tatyana Pyntikova, Natalia Koutseva, Tina Graves, Colin Kremitzki, Wesley C Warren, Andrew G Clark, Elena Gaginskaya, Richard K Wilson, David C Page
Journal: Nature Genetics (2017)
The Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent
Authors: Joep E.C. Eding, Charlotte J. Demkes, Joshua M. Lynch, Anita G. Seto, Rusty L. Montgomery, Hillary M. Semus, Aimee L. Jackson, Marc Isabelle, Stefano Chimenti, Eva van Rooij
Journal: Molecular Therapy (2017)

MicroRNAs (miRNAs) are important regulators of biology and disease. Recent animal efficacy studies validate the therapeutic benefit of miRNA modulation and underscore the therapeutic value of miRNA-targeting oligonucleotides. However, whether disease conditions (stress) influence the pharmacological effects of an anti-miR is currently unknown. To study the effect of disease on target regulation after anti-miR treatment, we injected animals with anti-miR-208a, a synthetic oligonucleotide that inhibits the cardiomyocyte-specific miR-208a. Our data indicate that the presence of stress increases the number of regulated miR-208a targets, and that higher stress levels correlate with stronger target derepression. Additionally, the type of stress also influences which targets are regulated upon miR-208a inhibition. Studies in a large animal model indicate a similar stress-dependent anti-miR effect. Subsequent in vitro studies suggest that the influence of stress on anti-miR efficacy depends at least in part on increased cellular anti-miR uptake. These data indicate that the pharmacological effect of anti-miRs is stronger under disease conditions, and that both the type and severity of disease determine the therapeutic outcome. These facts will be important for assessing the therapeutic dose and predicting the therapeutic outcome when applying anti-miRs in a clinical setting.
High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia
Authors: Katarina Reinhardt, C. Michel Zwaan, Michael Dworzak, Jasmijn D.E. de Rooij, Gertjan Kaspers, Thomas Lehrnbecher, Henrik Hasle, Toralf Bernig, Jean-Michel Cavuela, Alexandra Kolenova, Jochen Harbott, Jean-Pierre Bourquin, Jan Stary, Ursula Creutzig, Dirk Reinhardt
Journal: Blood (2012)
Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.
Authors: William G. Wierda, X. Wang, S. OBrien, S. Faderl, A. Ferrajoli, D. Thomas, F. Ravandi, J. Cortes, F. Giles, C. Koller, H. Kantarjian, S. Lerner, M. Keating
Journal: Blood (2005)
Dual‐photon microscopy‐based quantitation of fibrosis‐related parameters (q‐FP) to model disease progression in steatohepatitis
Authors: Yan Wang, Robert Vincent, Jinlian Yang, Amon Asgharpour, Xieer Liang, Michael O. Idowu, Melissa J. Contos, Kalyani Daitya, Mohammed S. Siddiqui, Faridoddin Mirshahi, Arun J. Sanyal
Journal: Hepatology (2017)

There is a need for further refinement of current histological systems for assessment of hepatic fibrosis in nonalcoholic fatty liver disease (NAFLD). This study evaluated hepatic fibrosis in NAFLD using dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FPs). Fifty test cohort subjects and 42 validation cohort subjects with NAFLD and the full spectrum of fibrosis were studied. q-FPs were measured in specific predefined regions of interest (general, vessel, perisinusoid, and vascular septa). Seventy q-FPs had inter- and intraobserver concordance ≥0.8 and were related to the NASH Clinical Research Network fibrosis staging. Of these, 16 q-FPs with the strongest correlations (P < 0.001 for all) were entered in a principal component analysis model (odds ratio [OR] 7.8, P < 0.001), which separated any stage of fibrosis versus no fibrosis, and cirrhosis versus earlier stages with the areas under the receiver operating characteristic curves of 0.88 and 0.93 (P ≤ 0.01 for both), respectively. In an independent multivariable analysis, four q-FPs-the number of collagen strands (OR 8.5, P = 0.004), strand length (OR 12.0, P = 0.02), strand eccentricity (OR 8.3, P = 0.004), and strand solidity (OR 8.0, P = 0.003)-were independently associated with fibrosis stages and were used to model fibrosis along a continuous linear scale using desirability functions; this linear scale of fibrosis measurement was also related to fibrosis stage (P < 0.0001). The robustness of both the multivariable model and the linear scale of measurement was confirmed in the validation cohort.The q-FP model provides an accurate reproducible method to evaluate fibrosis in NAFLD along a quantitative and continuous scale. (Hepatology 2017;65:1891-1903).
Poly ADP Ribose Polymerase (PARP) Inhibitors Induce Apoptosis Alone or Synergistically with Histone Deacetylase Inhibitors in Primary Acute Myeloid Leukemic Patient Cells
Authors: Terry J Gaymes, Sydney Shall, Farzin Farzaneh, Ghulam J Mufti
Journal: Blood (2008)
Store-Operated Ca 2+ Entry Controls Induction of Lipolysis and the Transcriptional Reprogramming to Lipid Metabolism
Authors: Mate Maus, Mario Cuk, Bindi Patel, Jayson Lian, Mireille Ouimet, Ulrike Kaufmann, Jun Yang, Rita Horvath, Hue-Tran Hornig-Do, Zofia M. Chrzanowska-Lightowlers, Kathryn J. Moore, Ana Maria Cuervo, Stefan Feske
Journal: Cell Metabolism (2017)
Terminal prognosis for the NHS
Authors: Malcolm Bourne
Journal: BMJ (2017)

I respond to Wollaston’s commentary on the NHS in 2017 as a consultant child and adolescent psychiatrist of more than 20 years.1

I find it incomprehensible that a doctor is a member of a government that is deliberately defunding and destabilising the NHS. The prime minister frequently talks about correcting social injustice but continues to …
Vitamin D deficiency in patients with pancreatic cancer.
Authors: Andrea Wang-Gillam, Kevin Ding, May Cho, Albert C. Lockhart, Ling Chen, Beth Zubal, Benjamin Tan
Journal: Journal of Clinical Oncology (2012)

353 Background: Vitamin D deficiency is common in many cancer patients but little is known about the vitamin D status in patients with pancreatic cancer. Frequently, patients with pancreatic cancer have malabsorption syndrome, and since vitamin D is fat soluble, it is likely to be deficient in this population. Methods: We conducted a retrospective review on patients with pancreatic cancer who were treated at Siteman Cancer Center (SCC). Patients’ demographic information, clinical staging at the time of vitamin D assessment, vitamin D status and survival data were collected. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D [(25(OH)D] &lt;20 ng/mL; vitamin D insufficiency was defined as 25(OH)D &lt;30 but &gt;20. Results: Between Dec 2007 and June 2011, 184 out of 625 pancreatic cancer patients had their vitamin D level checked at least once. Median age was 64 (range 34-86); 87 patients were female and 97 were male. The majority (159) were Caucasian. Sixty-four (34.8%) patients were post resection, while 34 (18.5%) and 86 (46.7%) had local disease and metastatic disease, respectively. Out of 184, 43 (23.3%) patients had normal vitamin D levels, while 53 (28.8%) and 88 (47.85%) were found to be vitamin D insufficient and deficient, respectively. All 28 non-Caucasian patients had either vitamin D deficiency or insufficiency, and their median 25(OH)D level was 11 ng/mL, compared to 21 ng/mL for Caucasian patients. The median 25(OH)D level was 17.5 ng/mL in patients with resected cancer, 22 ng/mL in patients with local disease, and 23 ng/mL in patients with metastatic disease. After adjusting age and stage, 25(OH)D &lt;20 ng/mL was found to be an independent prognostic factor (p= 0.071). Conclusions: Vitamin D insufficiency and deficiency is prevalent amongst our patients with all stages of pancreatic cancer. Vitamin D appears to be prognostic and should routinely be assessed in patients with pancreatic cancer.
COPD severity related to extended measurements of lung volume, diffusion, and resistance
Authors: Linnea Jarenbäck, Göran Eriksson, Stefan Peterson, Leif Bjermer, Ellen Tufvesson
Journal: European Respiratory Journal (2014)

Background:  We have previously shown that use of only FEV1 in COPD diagnosis and monitoring gives an incomplete characterization of the COPD patients. The aim of this post hoc study was to relate the severity of COPD to more advanced measures of lung function in COPD patients and healthy smokers by analyzing the data continuously.   Method:  Lung function of 65 COPD patients (GOLD 1-4) and 34 healthy smokers was tested using flow-volume spirometry, body plethysmography, single breath helium dilution with CO-diffusion and impulse oscillometry after 400μg salbutamol and 80 mg ipratropium. Relation between spirometric disease severity and different lung function measurements was descriptively analyzed with a flexible non-parametric smoothed fit (LOESS), linear regression (LR), as well as segmented linear regression (SLR). For SLR a cut point (CP) was determined and tested for relevance (p>0.05 was classified as no CP).   Results:  Following lung function variables were better described by SLR (CP: Mean%): FEV1/FVC (CP;72%), TLC%p (65%), FRC%p (65%), RV%p (64%), Rtot%p (82%), DLCO/VA%p (69%), RV bb-co %p (62%), AX (64%), X5 abs (63%). LR was selected for the remaining variables (p>0.05): FEV1%p, R ex , R in  (p=0.054), DLCO%p, RV co %p, VA%p, R20%p, R5%p, R5-20%p.   Conclusion:  Different lung function variables measured with different techniques can give important information about the severity of COPD. Many volume-related outcomes showed a break-point around 65% post-FEV1 and is probably related to increased air trapping. The finding is in the middle of GOLD 2 and might have implication for selection of outcomes depending of study population or vice versa.
RUNX1/CBFA2 Regulates Myosin Light Chain 9 (MYL9) in Megakaryocytic Cells: Decreased MYL9 Expression in Human RUNX1 Haplodeficiency.
Authors: Gauthami S Jalagadugula, Gurpreet Kaur, Guangfen Mao, Danny Dhanasekaran, A. Koneti Rao
Journal: Blood (2008)
Thrombin Inhibition Prevents Against Severe Atherosclerosis Progression in Prothrombotic Mice
Authors: Henri M.H. Spronk, Julian I Borissoff, Oliver Soehnlein, Rory Koenen, Rene van Oerle, Sylvia Heeneman, Mat J.A.P. Daemen, Charles T Esmon, Jay L. Degen, Hartmut Weiler, Joanne van Ryn, Hugo Ten Cate
Journal: Blood (2012)
Review: Some drugs, added to hydration, prevent contrast-induced acute kidney injury
Authors: Catherine M. Clase
Journal: Annals of Internal Medicine (2017)

Source Citation Su X, Xie X, Liu L, et al. Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and Bayesian network meta-analysis. Am J Kidney Dis. 2016 Oct 1. [Epub ahead of print]. 27707552
Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer
Authors: Hirofumi Saiki, Ivy A. Petersen, Christopher G. Scott, Kent R. Bailey, Shannon M. Dunlay, Randi R. Finley, Kathryn J. Ruddy, Elizabeth Yan, Margaret M. Redfield
Journal: Circulation (2017)

Cardiomyocytes are resistant to radiation. However, cardiac radiation exposure causes coronary microvascular endothelial inflammation, a perturbation implicated in the pathogenesis of heart failure (HF) and particularly HF with preserved ejection fraction (HFpEF). Radiotherapy for breast cancer results in variable cardiac radiation exposure and may increase the risk of HF.We conducted a population-based case-control study of incident HF in 170 female residents of Olmsted County, Minnesota (59 cases and 111 controls), who underwent contemporary (1998-2013) radiotherapy for breast cancer with computed tomography-assisted radiotherapy planning. Controls were matched to cases for age, tumor side, chemotherapy use, diabetes mellitus, and hypertension. Mean cardiac radiation dose (MCRD) in each patient was calculated from the patient's computed tomography images and radiotherapy plan.Mean age at radiotherapy was 69±9 years. Of HF cases, 38 (64%) had EF≥50% (HFpEF), 18 (31%) had EF<50% (HF with reduced EF), and 3 (5%) did not have EF measured. The EF was ≥40% in 50 of the 56 HF cases (89%) with an EF measurement. The mean interval from radiotherapy to HF was 5.8±3.4 years. The odds of HF was higher in patients with a history of ischemic heart disease or atrial fibrillation. The MCRD was 2.5 Gy (range, 0.2-13.1 Gy) and higher in cases (3.3±2.7 Gy) than controls (2.1±2.0 Gy; P=0.004). The odds ratio (95% confidence interval) for HF per log MCRD was 9.1 (3.4-24.4) for any HF, 16.9 (3.9-73.7) for HFpEF, and 3.17 (0.8-13.0) for HF with reduced EF. The increased odds of any HF or HFpEF with increasing MCRD remained significant after adjustment for HF risk factors and in sensitivity analyses matching by cancer stage rather than tumor side. Only 18.6% of patients experienced new or recurrent ischemic events between radiotherapy and the onset of HF.The relative risk of HFpEF increases with increasing cardiac radiation exposure during contemporary conformal breast cancer radiotherapy. These data emphasize the importance of radiotherapy techniques that limit MCRD during breast cancer treatment. Moreover, these data provide further support for the importance of coronary microvascular compromise in the pathophysiology of HFpEF.
Successful Mobilization with the Combination of Plerixafor and G-CSF in Korean Pediatric Patients Who Failed in Previous Chemomobilization with G-CSF Alone
Authors: Hyoung Jin Kang, Kyung Taek Hong, Nam Hee Kim, Min Sun Kim, Ji Won Lee, Hyery Kim, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn
Journal: Blood (2011)